<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6968547</article-id><article-id pub-id-type="pmid">31899981</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1707197</article-id><article-id pub-id-type="publisher-id">1707197</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Design, synthesis and cholinesterase inhibitory properties of new oxazole benzylamine derivatives</article-title><alt-title alt-title-type="left-running-head">I. &#x00160;agud et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Enzyme Inhibition and Medicinal Chemistry</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>&#x00160;agud</surname><given-names>Ivana</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><name><surname>Ma&#x0010d;ek Hrvat</surname><given-names>Nikolina</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><name><surname>Grgi&#x0010d;evi&#x00107;</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>&#x0010c;ade&#x0017e;</surname><given-names>Tena</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Hodak</surname><given-names>Josipa</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Dragojevi&#x00107;</surname><given-names>Milena</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Lasi&#x00107;</surname><given-names>Kornelija</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Kovarik</surname><given-names>Zrinka</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>&#x00160;kori&#x00107;</surname><given-names>Irena</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0002"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb</institution>, <city>Zagreb</city>, <country>Croatia</country></aff><aff id="AF0002"><label>b</label><institution>Institute for Medical Research and Occupational Health, Biochemistry and Analytic Organic Chemistry Unit</institution>, <city>Zagreb</city>, <country>Croatia</country></aff><aff id="AF0003"><label>c</label><institution>TEVA, Pliva Tapi R&#x00026;D</institution>, <city>Zagreb</city>, <country>Croatia</country></aff></contrib-group><author-notes><fn id="FN0001"><label>*</label><p>These authors equally contributed to this work.</p></fn><fn id="AUFN2"><p>Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1707197"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Zrinka Kovarik <email>zkovarik@imi.hr</email><institution>Institute for Medical Research and Occupational Health, Biochemistry and Analytic Organic Chemistry Unit</institution>, <city>Zagreb</city>, <postal-code>10001</postal-code><country>Croatia</country>; </corresp><corresp id="AN0002">Irena &#x00160;kori&#x00107; <email>iskoric@fkit.hr</email><institution>Department of Organic Chemistry, University of Zagreb Faculty of Chemical Engineering and Technology</institution>, <addr-line>Trg Marka Maruli&#x00107;a 19</addr-line>, <postal-code>10000</postal-code>, <city>Zagreb</city>, <country>Croatia</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>3</day><month>1</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="47">460</fpage><lpage>467</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1707197.pdf"/><abstract><title>Abstract</title><p>The enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are primary targets in attenuating the symptoms of neurodegenerative diseases. Their inhibition results in elevated concentrations of the neurotransmitter acetylcholine which supports communication among nerve cells. It was previously shown for <italic>trans-</italic>4/5-arylethenyloxazole compounds to have moderate AChE and BChE inhibitory properties. A preliminary docking study showed that elongating oxazole molecules and adding a new NH group could make them more prone to bind to the active site of both enzymes. Therefore, new <italic>trans-</italic>amino-4-/5-arylethenyl-oxazoles were designed and synthesised by the Buchwald-Hartwig amination of a previously synthesised <italic>trans-</italic>chloro-arylethenyloxazole derivative. Additionally, naphthoxazole benzylamine photoproducts were obtained by efficient photochemical electrocyclization reaction. Novel compounds were tested as inhibitors of both AChE and BChE. All of the compounds exhibited binding preference for BChE over AChE, especially for <italic>trans-</italic>amino-4-/5-arylethenyl-oxazole derivatives which inhibited BChE potently (IC<sub>50</sub> in &#x000b5;M range) and AChE poorly (IC<sub>50</sub>&#x0226b;100&#x02009;&#x000b5;M). Therefore, due to the selectivity of all of the tested compounds for binding to BChE, these compounds could be applied for further development of cholinesterase selective inhibitors.<list list-type="bullet"><title>HIGHLIGHTS</title><list-item><p>Series of oxazole benzylamines were designed and synthesised</p></list-item><list-item><p>The tested compounds showed binding selectivity for BChE</p></list-item><list-item><p>Naphthoxazoles were more potent AChE inhibitors</p></list-item></list></p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Arylethenyl-oxazole</kwd><kwd>benzylamine</kwd><kwd>cholinesterase</kwd><kwd>electrocyclization</kwd><kwd>naphthoxazole</kwd><kwd>synthesis</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Croatian Science Foundation</institution></institution-wrap></funding-source><award-id>IP-2018&#x02013;01-7683</award-id></award-group><funding-statement>This work was supported by the Croatian Science Foundation [project IP-2018&#x02013;01-7683]. </funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="8"/><word-count count="6807"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) are two related enzymes present in vertebrates and plants. In humans, these enzymes are products of different genes but share about 54% of their amino acid sequence<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. The major difference in their active site are the 14 aromatic amino acid residues in AChE which correspond to 8 aromatic and 6 aliphatic residues in BChE<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. This enables BChE to hydrolyse larger substrates and ligands than AChE and is accountable for the binding selectivity of cholinesterases<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;6</sup></xref>.</p><p>AChE has an essential physiological role in the body as it controls the transmission of nerve impulses in the cholinergic synapses of the central and peripheral nervous system by hydrolysis of the neurotransmitter acetylcholine. It also has a role in neuritogenesis, cell adhesion, proliferation and cell interactions, synaptogenesis, dopamine neuronal activation, the formation of amyloid fibres characteristic for Alzheimer's disease, haematopoiesis and thrombopoiesis<xref rid="CIT0007" ref-type="bibr"><sup>7&#x02013;9</sup></xref>. The role of BChE is not physiologically essential but it could be assigned to the detoxification of xenobiotics (organophosphates and carbamate pesticides, cocaine, aspirin, succinyldicholine, etc.) and bioactivation of drugs (bambuterol, heroin, etc.)<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>. Also, BChE serves as a co-regulator of cholinergic neurotransmission and is capable of catalysing the hydrolysis of acetylcholine<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>. It was found that high BChE levels are associated with neuritic plaques and neurofibrillary tangles, the neuropathologic hallmarks of Alzheimer&#x02019;s disease (AD)<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. Therefore, both cholinesterases are pharmacologically relevant targets in neurodegenerative disorders, and today&#x02019;s treatment includes cholinesterase inhibitors like donepezil, galantamine, physostigmine, rivastigmine, ect.<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>. Many other compounds acting as inhibitors of cholinesterase are therefore considered as potential AD therapeutics<xref rid="CIT0016" ref-type="bibr"><sup>16&#x02013;18</sup></xref>.</p><p>Recently we have shown that 4/5-arylethenyloxazoles possess a moderate potency to inhibit AChE and BChE<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>. In this study, we designed new <italic>trans-</italic>amino-5-arylethenyl-oxazole derivatives where the oxazole molecule has an NH group on one of the substituents. For the synthesis of styryl-oxazoles, the Van Leusen reaction was utilised. Styryl-oxazole that has chlorine as a substituent was then <italic>N</italic>-alkylated by Buchwald-Hartwig type reaction to give oxazole benzylamines which were tested as cholinesterase inhibitors. All of the styryl-oxazole amines were also photochemically cyclized to give naphthoxazole benzylamines<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. Naphthoxazoles synthesised by this manner were also tested. This gave a wide range of molecules with either oxazole or the naphthoxazole moiety to evaluate their impact on the cholinesterase inhibitory activity.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Results and discussion</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Synthesis and photochemistry of novel oxazole benzylamines</title><p>Using the reaction of <italic>N</italic>-alkylation on the previously synthesised <italic>trans-</italic>chloro-arylethenyloxazole <bold>1</bold><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>, new <italic>trans-</italic>amino-5-arylethenyl-oxazole derivatives <italic>trans-</italic><bold>2&#x02013;18</bold> were synthesised (<xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>) with an aim to add a new functional group at the end of the oxazole derivative that resembles acetylcholine, the substrate of cholinesterase. The Buchwald-Hartwig reaction<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref> was utilised with two catalysts and the reaction was optimised for best conditions to enhance the yield. Change of base was crucial for the optimisation of this reaction. Sodium <italic>tert</italic>-butoxide was previously used as a base but the dehalogenation of the starting material was observed. Caesium carbonate improved yield and conversion. Temperature, solvent and catalyst used were independently varied to give the best conversion. The best conditions found are given in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>. The catalysed <italic>N</italic>-alkylation reaction is a complex coupling reaction and it gave a vast array of yields. Some of the substrates were optimised to excellent yields, while in the example of others only moderate to low yields were obtained. There is still some room for optimisation in the future with additional catalysts but at this time this was sufficient.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of targeted compounds <italic>trans-</italic><bold>2&#x02013;18</bold> by Buchwald-Hartwig reaction.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1707197_SCH0001_C"/></fig><p>A vast number of new compounds was synthesised and spectroscopically characterised (See <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1707197">experimental and Supplementary Figures S1&#x02013;S19</ext-link>). Compounds with a pyridine ring <bold>15</bold> and <bold>16</bold> and that bearing 2-chlorophenyl substituent <bold>13</bold> were synthesised only in trace amounts and these compounds were not further investigated. Pyridine derivatives <bold>15</bold> and <bold>16</bold> could not be obtained probably because of the influence of basicity of the heteroaromatic ring containing nitrogen on the complex reaction steps of Buchwald-Hartwig amination reaction. Only some of the compounds (<italic>trans</italic>-<bold>2</bold>, <italic>trans</italic>-<bold>6</bold> and <italic>trans</italic>-<bold>18</bold>) were successfully photochemically cyclized into novel polycyclic derivatives <bold>19&#x02013;21</bold> (<xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>). Other starting amines did not react in the electrocyclization reaction and remained unreacted in the reaction solution, some of them as mixture of configurational isomers. The photochemically reactive anilines showed <italic>cis</italic>-<italic>trans</italic> photoisomerization during the photoreaction and as the consequence of that gave photocyclization products <bold>19&#x02013;21</bold> as only <italic>cis</italic>-configuration is suitable for electrocyclization. Only the <italic>cis</italic>-isomer of the amine <bold>18</bold> was isolated from the photomixture after the cyclisation reaction, and spectroscopically characterised. It does not mean that the photostationary state is not established in the photomixture in the case of other amines, but without further electrocyclization reaction. During the photocyclization of 2-thienyl (<italic>trans-</italic><bold>18</bold>) derivative, the competitive cleavage of the heteroaromatic moiety occurred resulting in the isolation of the <italic>cis</italic>-<bold>22</bold> and its electrocyclization product <bold>23</bold>. The same products were seen also in the <sup>1</sup>H NMR spectrum after photoreaction of <italic>trans</italic>-<bold>17</bold>. The difference between these two heteroaromatic amines is that <italic>trans</italic>-<bold>17</bold> does not cyclize to the corresponding electrocyclization product and gave these products only in traces. The formation of the same product <bold>23</bold> can be also explained as the consequence of the cleavage of the heteroaromatic moiety from <bold>21</bold> (<xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>) and this pathway of formation of <bold>23</bold> cannot be excluded as both pathways can occur as competitive processes in the same photoreaction.</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Photochemical reactivity of amino-5-arylethenyl-oxazoles <italic>trans</italic>-<bold>2,6,18</bold> into naphtho[1,2-<italic>d</italic>]oxazoles, <bold>19</bold>,<bold>20</bold> and <bold>21</bold>, respectively.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1707197_SCH0002_C"/></fig><p>All compounds were completely spectroscopically characterised. On <xref ref-type="fig" rid="F0001">Figure 1</xref>, UV spectra are given as they are used in the determination of wavelength in cyclisation reactions. Absorption maxima of all of the starting <italic>trans</italic>-isomers of compounds <bold>2&#x02013;18</bold> are in the area between 340&#x02009;nm and 350&#x02009;nm and that is the reason why irradiation at 350&#x02009;nm wavelength was used for cyclisation.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>UV spectra of compounds <italic>trans-</italic><bold>2</bold> and <italic>trans-</italic><bold>17</bold> (a), <italic>para</italic>-substituted synthesised compounds <italic>trans-</italic><bold>3&#x02013;6</bold> (b), <italic>meta</italic>-substituted synthesised compounds <italic>trans-</italic><bold>7&#x02013;10</bold> (c) and <italic>ortho</italic>-substituted synthesised compounds <italic>trans-</italic><bold>11</bold>, <italic>trans-</italic><bold>12</bold> and <italic>trans-</italic><bold>14</bold> (d).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1707197_F0001_C"/></fig><p>All isolated compounds exhibited in the <sup>1</sup>H NMR spectrum a singlet in the range of 7.78&#x02013;7.81&#x02009;ppm, which was attributed to the proton on the position 2 of the oxazole ring due to the influence of nitrogen and oxygen found in its immediate vicinity unshaded and shifted to a lower field (<xref ref-type="fig" rid="F0002">Figure 2</xref> and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1707197">Supplementary Figures S1&#x02013;S19</ext-link>). The protons located at position 4 of the oxazole ring showed a singlet in the range of 6.95&#x02013;6.99&#x02009;ppm, the ethylenic protons are visible as doublets in the range of 6.99&#x02013;7.08&#x02009;ppm with coupling constants between 16&#x02009;Hz and 17&#x02009;Hz, characteristic for <italic>trans</italic>-isomers. For compounds <italic>trans-</italic><bold>17</bold> and <italic>trans-</italic><bold>18</bold>, the characteristic signals for the furan or thiophene ring are also visible with characteristic coupling constants (See <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1707197">experimental and Supplementary Figure S16</ext-link>). In the spectra of electrocyclization products <bold>19&#x02013;21,</bold> two new doublets with <italic>cis</italic> coupling constants appeared, characteristic for the central ring of the cyclized naphthoxazole. The structure and purity of the synthesised amines were also confirmed by <sup>13&#x02009;</sup>C NMR and two-dimensional NMR techniques as well as HRMS analyses (See <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1707197">experimental and Supplementary Figures S1&#x02013;S19</ext-link>).</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Partial <sup>1</sup>H NMR spectra of starting amines <italic>trans-</italic><bold>2</bold> and <italic>trans-</italic><bold>17</bold> and of the photocyclization product <bold>19</bold>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1707197_F0002_C"/></fig></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Inhibition of cholinesterases by novel oxazole benzylamines</title><p>The eleven new synthetised <italic>trans-</italic>amino-5-arylethenyl-oxazole derivatives (<italic>trans</italic>-<bold>2</bold>-<italic>trans</italic>-<bold>12</bold>, and <italic>trans</italic>-<bold>17</bold>) were tested in a wide concentration range as BChE inhibitors to evaluate the inhibitor concentration that inhibits 50% of enzyme activity (IC<sub>50</sub>), presented in <xref rid="t0001" ref-type="table">Table 1</xref>. The most potent BChE inhibitors were compounds <italic>trans-</italic><bold>12</bold>, <italic>trans-</italic><bold>10</bold> and <italic>trans-</italic><bold>8</bold> with an IC<sub>50</sub> of about 30&#x02009;&#x000b5;M. BChE had the lowest binding affinity for compound <italic>trans-</italic><bold>11</bold> which was 5.5-fold lower than the most potent inhibitor <italic>trans-</italic><bold>12</bold>. It is interesting to note that the binding affinity of BChE for compounds <italic>trans-</italic><bold>12</bold>, <italic>trans-</italic><bold>10</bold> and <italic>trans-</italic><bold>8</bold> was similar as reported for cholinesterase inhibitors BW284C51, huperzine or rivastigmine (IC<sub>50</sub> 30 &#x02013; 54&#x02009;&#x000b5;M)<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Inhibition of BChE and AChE by tested <italic>trans-</italic>amino-5-arylethenyl-oxazole derivatives (<italic>trans</italic>-<bold>2</bold>-<italic>trans</italic>-<bold>17</bold>), naphtho[1,2-<italic>d</italic>]oxazoles (<bold>19</bold>&#x02013;<bold>21</bold> and <bold>23),</bold> and amino-4/5-arylethenyl-oxazoles (<italic>cis</italic>-<bold>18</bold> and <italic>cis</italic>-<bold>22)</bold>, expressed as IC<sub>50</sub> &#x000b1; SE.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="2" align="center">IC<sub>50</sub> (&#x000b5;M)<hr/></th></tr><tr><th align="left">Compound (aromatic/heteroaromatic substitution)</th><th align="center">BChE</th><th align="center">AChE</th></tr></thead><tbody valign="top"><tr><td align="left"><italic toggle="yes">trans-</italic><bold>2</bold> (phenyl)</td><td align="char" char="&#x000b1;">120&#x02009;&#x000b1;&#x02009;22</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>3</bold> (<italic toggle="yes">p</italic>-methylphenyl)</td><td align="char" char="&#x000b1;">120&#x02009;&#x000b1;&#x02009;19</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>4</bold> (<italic toggle="yes">p</italic>-methoxyphenyl)</td><td align="char" char="&#x000b1;">110&#x02009;&#x000b1;&#x02009;15</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>5</bold> (<italic toggle="yes">p</italic>-chlorophenyl)</td><td align="char" char="&#x000b1;">87&#x02009;&#x000b1;&#x02009;12</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>6</bold> (<italic toggle="yes">p</italic>-fluorophenyl)</td><td align="char" char="&#x000b1;">80&#x02009;&#x000b1;&#x02009;10</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>7</bold> (<italic toggle="yes">m</italic>-methylphenyl)</td><td align="char" char="&#x000b1;">130&#x02009;&#x000b1;&#x02009;26</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>8</bold> (<italic toggle="yes">m</italic>-methoxyphenyl)</td><td align="char" char="&#x000b1;">36&#x02009;&#x000b1;&#x02009;4.4</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>10</bold> (<italic toggle="yes">m</italic>-fluorophenyl)</td><td align="char" char="&#x000b1;">32&#x02009;&#x000b1;&#x02009;5.2</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>11</bold> (<italic toggle="yes">o</italic>-methylphenyl)</td><td align="char" char="&#x000b1;">160&#x02009;&#x000b1;&#x02009;35</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>12</bold> (<italic toggle="yes">o</italic>-methoxyphenyl)</td><td align="char" char="&#x000b1;">28&#x02009;&#x000b1;&#x02009;5.2</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><italic toggle="yes">trans-</italic><bold>17</bold> (2-furyl)</td><td align="char" char="&#x000b1;">65&#x02009;&#x000b1;&#x02009;10</td><td align="center">&#x0226b;100</td></tr><tr><td align="left"><bold>19</bold> (phenyl)</td><td align="char" char="&#x000b1;">140&#x02009;&#x000b1;&#x02009;24</td><td align="char" char="&#x000b1;">68&#x02009;&#x000b1;&#x02009;25</td></tr><tr><td align="left"><bold>20</bold> (<italic toggle="yes">p</italic>-fluorophenyl)</td><td align="char" char="&#x000b1;">12&#x02009;&#x000b1;&#x02009;1.3</td><td align="char" char="&#x000b1;">45&#x02009;&#x000b1;&#x02009;17</td></tr><tr><td align="left"><bold>21</bold> (2-thienyl)</td><td align="char" char="&#x000b1;">35&#x02009;&#x000b1;&#x02009;7.1</td><td align="char" char="&#x000b1;">51&#x02009;&#x000b1;&#x02009;20</td></tr><tr><td align="left"><bold>23</bold></td><td align="char" char="&#x000b1;">1000&#x02009;&#x000b1;&#x02009;650</td><td align="char" char="&#x000b1;">120&#x02009;&#x000b1;&#x02009;46</td></tr><tr><td align="left"><italic toggle="yes">cis</italic>-<bold>22</bold></td><td align="char" char="&#x000b1;">110&#x02009;&#x000b1;&#x02009;58</td><td align="char" char="&#x000b1;">190&#x02009;&#x000b1;&#x02009;100</td></tr><tr><td align="left"><italic toggle="yes">cis</italic>-<bold>18</bold> (<italic toggle="yes">p</italic>-fluorophenyl)</td><td align="char" char="&#x000b1;">5.7&#x02009;&#x000b1;&#x02009;0.8</td><td align="char" char="&#x000b1;">160&#x02009;&#x000b1;&#x02009;100</td></tr><tr><td align="left">Ethopropazine</td><td align="char" char="&#x000b1;">0.046&#x02009;&#x000b1;&#x02009;0.0037</td><td align="char" char="&#x000b1;">73&#x02009;&#x000b1;&#x02009;8.3</td></tr></tbody></table></table-wrap><p>Generally, although these compounds, with the exception of compound <italic>trans-</italic><bold>17</bold>, systematically differ only by their substituent on the benzyl group and its substituent position (<italic>ortho-, meta-, para-</italic>), this structural variation cannot be easily related to IC<sub>50</sub> values. The most potent inhibitors, compounds <italic>trans-</italic><bold>12</bold>, <italic>trans-</italic><bold>10</bold> and <italic>trans-</italic><bold>8</bold> have <italic>ortho</italic>-methoxy, <italic>meta</italic>-fluoro and <italic>meta</italic>-methoxy substituents at the phenyl rings, respectively. Moreover, <italic>ortho</italic>- (<italic>trans-</italic><bold>12</bold>) and <italic>meta</italic>- (<italic>trans-</italic><bold>8</bold>) analogues had about a 3 times lower IC<sub>50</sub> than their <italic>para</italic>-methoxy analogue (<italic>trans-</italic><bold>4</bold>). Similarly, the <italic>meta-</italic>fluoro substituted compound, <italic>trans-</italic><bold>10</bold>, exhibited a 2.5 times lower IC<sub>50</sub> than its <italic>para</italic>-fluoro analogue, <italic>trans-</italic><bold>6</bold>. In case of the methyl substituent, the position of the substituent was not relevant because all three compounds (<italic>trans-</italic><bold>3</bold>, <italic>trans-</italic><bold>7</bold> and <italic>trans-</italic><bold>11</bold>) had a similar IC<sub>50</sub> and were the weakest inhibitors among the tested compounds (<xref rid="t0001" ref-type="table">Table 1</xref>). Nevertheless, the <italic>para</italic>-substitution and methyl-substitution led to inactive compounds, while the <italic>ortho</italic>/<italic>meta</italic>-methoxy and the <italic>meta</italic>-fluoro were active derivatives. It is not surprising that the activity was noticeably different between the most potent (<italic>trans-</italic><bold>12</bold>) and the weakest inhibitor (<italic>trans-</italic><bold>11</bold>) differed in the methoxy and methyl substituent at position 2, respectively.</p><p>Eleven <italic>trans</italic>-amino-5-arylethenyl-oxazole derivatives inhibited maximally 20% of AChE activity (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1707197">Supplementary Figure S20</ext-link>) and IC<sub>50</sub> values were not determined. Since higher concentrations than 100&#x02009;&#x000b5;M could not be used due to AChE inhibition by solvent DMSO<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>, the IC<sub>50</sub> values for AChE were presumably much higher than 100&#x02009;&#x000b5;M.</p><p>Four of the polycyclic naphtho[1,2-<italic>d</italic>]oxazoles compounds (<bold>19</bold>, <bold>20</bold>, <bold>21</bold>, <bold>23</bold>) and two isolated <italic>cis-</italic>isomers of amino-5-arylethenyl-oxazole derivatives (<italic>cis-</italic><bold>18</bold>, <italic>cis-</italic><bold>22</bold>) were also tested as potential inhibitors of cholinesterases. All compounds, except <bold>23</bold>, inhibited both enzymes more than 50% with concentrations in &#x000b5;M range and the evaluated IC<sub>50</sub> values are given in <xref rid="t0001" ref-type="table">Table 1</xref>. The IC<sub>50</sub> for BChE and compound <italic>cis-</italic><bold>18</bold> was the lowest IC<sub>50</sub> value evaluated in this study. <italic>cis</italic>-<bold>18</bold> was about 5 times more potent inhibitor of BChE than amino-5-arylethenyl-oxazoles <italic>trans</italic>-<bold>12</bold>, <italic>trans</italic>-<bold>10</bold> and <italic>trans</italic>-<bold>8</bold> (<xref rid="t0001" ref-type="table">Table 1</xref>). It is also interesting to note that <italic>cis-</italic><bold>18</bold> and <italic>cis-</italic><bold>22</bold> exhibited a higher inhibition effect for BChE than their electrocyclic products <bold>21</bold> and <bold>23</bold>, respectively, while polycyclic derivative <bold>20</bold> had about 8-fold higher potency for BChE than its counterpart <italic>trans</italic>-<bold>6</bold> (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p>In the case of AChE, it seems that the electrocyclization and <italic>trans-cis</italic> isomerisation of amino-5-arylethenyl-oxazole derivatives enabled additional interactions in the active site improving the inhibition potency. The electrocyclization of <italic>cis</italic>-<bold>18</bold> and <italic>cis</italic>-<bold>6</bold> resulted in the thienyl-naphtho[1,2-<italic>d</italic>]oxazole, <bold>21</bold>, and <italic>p</italic>-fluorophenyl-naphtho[1,2-<italic>d</italic>]oxazole, <bold>20</bold>, respectively. Both compounds <bold>21</bold> and <bold>20</bold> are potent inhibitors of AChE. The naphtho[1,2-<italic>d</italic>]oxazole without aminoalkyl substituent <bold>23</bold> was the poorest inhibitor out of the six tested compounds (<xref rid="t0001" ref-type="table">Table 1</xref>). Again, except for <bold>23,</bold> there was a slight binding preference of BChE. Therefore, generally, the obtained results indicate that the tested oxazole amines as well as naphtho[1,2-<italic>d</italic>]oxazole derivatives may be classified as selective inhibitors of BChE.</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Conclusions</title><p>New amino-5-arylethenyl-oxazoles <italic>trans</italic>-<bold>2&#x02013;18,</bold> and <italic>cis</italic>-<bold>18</bold> and <italic>cis</italic>-<bold>22,</bold> as well as naphthoxazole benzylamines <bold>19&#x02013;23</bold> were successfully synthesised using the reaction of <italic>N</italic>-alkylation on previously synthesised <italic>trans</italic>-chloro-arylethenyl-oxazole <bold>1</bold>. The IC<sub>50</sub> values evaluated for BChE classified the tested compounds as moderate BChE inhibitors. Naphtho[1,2-<italic>d</italic>]oxazoles showed to be more potent AChE inhibitors than the <italic>trans</italic>-amino-5-arylethenyl-oxazole derivatives, which inhibited 20% of AChE activity at most at the highest concentration possible to test. Due to the selectivity of tested oxazole benzylamines for binding to BChE, the scaffold of these compounds could be used for further development of cholinesterase selective inhibitors.</p></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Experimental section</title><sec id="S0004-S2001" disp-level="2"><label>4.1.</label><title>Chemistry</title><sec id="S0004-S2001-S3001" disp-level="3"><label>4.1.1.</label><title>General procedures</title><p>Reactions that required the use of anhydrous, inert atmosphere techniques were carried out under an atmosphere of nitrogen. Petroleum ether, bp 40&#x02013;60&#x02009;&#x000b0;C, was used. Solvents were purified by distillation. Column chromatography was carried out on columns with silica gel (Fluka 0.063&#x02013;0.2&#x02009;nm and Fluka 60&#x02009;&#x000c5;, technical grade). TLC was carried out using plates coated with silica gel (0.2&#x02009;mm, 0.5&#x02009;mm, 1.0&#x02009;mm, Kieselgel 60 F<sub>254</sub>). Organic layers were routinely dried with anhydrous MgSO<sub>4</sub> and evaporated using a rotary evaporator. <sup>1</sup>H and <sup>13&#x02009;</sup>C NMR spectra were recorded on a spectrometer at 300 and 600&#x02009;MHz. All NMR spectra were measured in CDCl<sub>3</sub> using tetramethylsilane as reference. The assignment of signals was based on 2&#x02009;D-CH correlation and 2&#x02009;D-HH-COSY experiments. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartette, dd, doublet of doublets; m, multiplet and br, broad. UV spectra were measured on a UV/VIS spectrophotometer. IR spectra were recorded on a FTIR. Mass spectra were obtained on a GC-MS system. Melting points were obtained using a microscope equipped apparatus and are uncorrected. HRMS analyses were carried out on a mass spectrometer. The LC-MS system consisted of an Agilent 1290 LC coupled with an Agilent 6550 iFunnel quadrupole time-of-flight mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). The LC-MS system equipped with a quaternary gradient pump, temperature-controlled column compartment, refrigerated autosampler component, diode array detector (DAD) and MS with electrospray ionisation were used for the identification. Chromatographic separations were performed using Acquity UPLC BEH C18 column, 50&#x02009;&#x000d7;&#x02009;2.1&#x02009;mm, 1.7&#x02009;&#x000b5;m (Agilent Technologies, Santa Clara, CA, USA). Gradient elution with mobile phase containing solvent A (0.1% formic acid) and solvent B (acetonitrile) was used. The mobile-phase flow rate was 0.4&#x02009;mL/min and the column temperature was maintained at 50&#x02009;&#x000b1;&#x02009;1&#x02009;&#x000b0;C. Substances were analysed in positive electrospray ionisation mode. Nitrogen was a nebuliser and curtain gas. The capillary voltage was 3500&#x02009;V. Gas temperature was 200&#x02009;&#x000b0;C, gas flow was 14&#x02009;L/min, nebuliser was 35&#x02009;psi, sheath gas temperature was 350&#x02009;&#x000b0;C and sheath gas flow was 11&#x02009;L/min. Data acquisition and processing were performed on a MassHunter Data Acquisition for Q-TOF B.06.01 (B6157) software (Agilent Technologies). Irradiation experiments were performed in a closed quartz vessel in toluene solution in a photochemical reactor equipped with 360&#x02009;nm lamps. The solvents were removed on the rotatory evaporator under reduced pressure in a ventilated hood.</p></sec><sec id="S0004-S2001-S3002" disp-level="3"><label>4.1.2.</label><title>Synthesis of (E)-5&#x02013;(4-chlorostyryl)oxazole (trans-1)</title><p>Compound <italic>trans</italic><bold>-1</bold> was synthesised from (<italic>E</italic>)-3&#x02013;(4-chlorophenyl)acryladehyde (6.00&#x02009;mmol, 1 eq) by Van Leusen reaction<sup>,</sup><xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref> with tosylmethylisocyanide (TosMIC) (5.76&#x02009;mmol, 0.96 eq) reagent and potassium carbonate as base (5.79&#x02009;mmol, 0.96 eq) in methanol. (<italic>E</italic>)-5&#x02013;(4-chlorostyryl)oxazole (<italic>trans</italic><bold>-1</bold>) of compound<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref> was isolated as yellow powder (0.950&#x02009;g; 77.24%): mp 78&#x02013;81&#x02009;&#x000b0;C; Rf (PE/E, 20%) = 0.59; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 299 (27977), 312 (29351), 326 (20895); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 1697, 1610, 1491, 1089; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 7.84 (s, 1H, H-2), 7.40 (dd, <italic>J</italic><sub>ar</sub>= 8.5&#x02009;Hz, <italic>J</italic><sub>ar</sub>= 6.6&#x02009;Hz, 2H, H-ar), 7.33 (dd, <italic>J</italic><sub>ar</sub>= 8.5&#x02009;Hz, <italic>J</italic><sub>ar</sub>= 6.6&#x02009;Hz, 2H, H-ar), 7.08 (s, 1H, H-4), 7.04 (d, <italic>J</italic><sub>et</sub> = 16.2&#x02009;Hz, 1H, H-et), 6.88 (d, <italic>J</italic><sub>et</sub> = 16.2&#x02009;Hz, 1H, H-et); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 150&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 150.63 (d), 149.23 (s), 147.54 (s), 137.03 (s), 132.58 (s), 129.92 (d), 128.33 (d), 128.12 (d), 127.52 (d), 125.52 (d), 122.11 (d), 112.48 (d), 108.52 (d), 46.88 (t); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 150&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 149.9 (d, C-2), 149.7 (s), 134.2 (s), 133.5 (s), 128.5 (d), 128.4 (d), 127.2 (d), 124.0 (d), 112.9 (d); MS <italic>m/z</italic> (EI) = 205 (100, M<sup>+</sup>); HRMS(Q-TOF) for C<sub>11</sub>H<sub>8</sub>ClNO: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 206.0294, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 206.0369.</p></sec><sec id="S0004-S2001-S3003" disp-level="3"><label>4.1.3.</label><title>Synthesis of new (E)-N-benzyl-4&#x02013;(2-(oxazol-5-yl)vinyl)anilines</title><sec id="S0004-S2001-S3003-S4001" disp-level="4"><label>4.1.3.1.</label><title>Synthesis with BrettPhos</title><p>BrettPhos (0.024&#x02009;mmol 0.1 eq), Pd(OAc)<sub>2</sub> (0.012&#x02009;mmol, 0.05 eq) were suspended in 2&#x02009;mL of dioxane with 0.01&#x02009;mL water and heated to 120&#x02009;&#x000b0;C. (<italic>E</italic>)-5&#x02013;(4-chlorostyryl)oxazole (0.243&#x02009;mmol, 1 eq) Cs<sub>2</sub>CO<sub>3</sub> (0.365&#x02009;mmol, 1,5 eq) and different benzyl-amines were added (0.486&#x02009;mmol, 2 eq). The reaction mixture was heated in a pressure tube to 110&#x02009;&#x000b0;C for 24&#x02009;h. Solvent was evaporated under pressure and the compound purified by column chromatography on silicagel using petroleumether/dichloromethane (20&#x02013;100%) as eluent.</p></sec><sec id="S0004-S2001-S3003-S4002" disp-level="4"><label>4.1.3.2.</label><title>Synthesis with XPhos</title><p>(<italic>E</italic>)-5&#x02013;(4-chlorostyryl)oxazole (0.243&#x02009;mmol, 1 eq), XPhos (0.049&#x02009;mmol, 0.2 eq), Pd(OAc)<sub>2</sub> (0.012&#x02009;mmol, 0.05 eq) and Cs<sub>2</sub>CO<sub>3</sub> (0.365&#x02009;mmol, 1.5 eq) were dissolved in 2&#x02009;mL of dioxane and benzyl-amines (0.486&#x02009;mmol, 2 eq) were added. The reaction mixture was purged with argon and heated to 110&#x02009;&#x000b0;C in a pressure tube for 24&#x02009;h. Solvent was evaporated under pressure and the compound purified by column chromatography on silica gel using petroleumether/dichloromethane (20&#x02013;100%) as eluent.</p><p>(<italic>E</italic>)-<italic>N</italic>-benzyl-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-2</bold>) was isolated (0.097&#x02009;g (72.22%)) as yellow powder: mp 112&#x02013;118&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.32; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 224 (32046), 319 (Sh, 11687), 343 (12469); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3421, 2924, 1748, 1607, 1524, 1490, 1453, 955, 817, 744, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.79 (s, 1H, H-Ox<sub>2</sub>), 7.37&#x02013;7.28 (m, 8H, H-Ar, H-NH), 7.00 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.07&#x02009;Hz, H-Et<sub>1</sub>), 6.97 (s, 1H, H-Ox<sub>4</sub>), 6.69 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.42&#x02009;Hz, H-Et<sub>2</sub>), 6.63 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.74&#x02009;Hz, H-Ar<sub>2a</sub>), 4.37 (s, 2H, H-CH<sub>2</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 149.22 (s), 147.88 (s), 138.46 (s), 130.04 (d), 128.21 (d), 127.51 (d), 126.97 (d), 126.88 (d), 125.27 (s), 122.02 (d), 112.38 (d), 108.33 (d), 47.59 (t); HRMS(Q-TOF) for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 277.1335, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 277.1325.</p><p>(<italic>E</italic>)-<italic>N</italic>-(4-methylbenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-3</bold>) was isolated (0.099&#x02009;g (70.92%)) as yellow powder mp 128&#x02013;131&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.43; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 242 (11249), 325 (Sh,15804), 346 (18719); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3416, 2925, 1612, 1577, 1558, 1519, 1476, 953, 820, 637; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H,H-Ox<sub>2</sub>), 7.32 (d, 2H, <italic>J</italic><sub>Ar1aAar2a</sub> = 8.58&#x02009;Hz, H-Ar<sub>1a</sub>), 7.27 (d, 2H, <italic>J</italic><sub>Ar3b,Ar4b</sub> = 7.82&#x02009;Hz, H-Ar<sub>3b</sub>), 7.18 (d, 2H, <italic>J</italic><sub>Ar4b,Ar3b</sub> = 7.82&#x02009;Hz, H-Ar<sub>4</sub>), 7.02 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.65&#x02009;Hz, H-Et<sub>1</sub>), 6.98 (s, 1H, H-Ox<sub>4</sub>), 6.70 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.40&#x02009;Hz, H-Et<sub>2</sub>), 6.63 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.58&#x02009;Hz, H-Ar<sub>2a</sub>), 4.34 (s, 2H, H-CH<sub>2</sub>), 4.21 (s, 1H, H-NH), 2.36 (s, 3H, H-CH<sub>3</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 147.95 (s), 136.56 (s), 135.38 (s), 130.10 (d), 128.88 (d), 127.51 (d), 126.93 (d), 125.16 (s), 122.01 (d), 112.36 (d), 108.25 (d), 47.34 (q), 20.58 (t); HRMS(Q-TOF) for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 291.1492, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 291.1487.</p><p>(<italic>E</italic>)-<italic>N</italic>-(4-methoxybenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-4</bold>) was isolated (0.054&#x02009;g (36.29%)) as yellow powder mp 153&#x02013;159&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.38; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 224 (16148), 328 (Sh, 19991), 350 (24578); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3376, 2925, 1601, 1514, 1468, 952, 822, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7,81 (s, 1H, H-Ox<sub>2</sub>), 7.34&#x02013;7.29 (m, 4H, H-Ar), 7.02 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.51&#x02009;Hz, H-Et<sub>1</sub>), 6.98 (s, 1H, H-Ox<sub>4</sub>), 6.90 (d, 2H, <italic>J</italic><sub>Ar1a,Ar2a</sub> = 8.77&#x02009;Hz, H-Ar<sub>1a</sub>), 6.70 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.26&#x02009;Hz, H-Et<sub>2</sub>), 0.63 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.51&#x02009;Hz, H-Ar<sub>2a</sub>), 4.31 (s, 1H, H-CH<sub>2</sub>), 4.17 (s, 1H, H-NH), 3.82 (s, 3H, H-OCH<sub>3</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 158.50 (s), 147.93 (s), 130.43 (s), 130.07 (d), 128.24 (d), 127.17 (s), 125.17 (s), 121.99 (d), 113.62 (d), 112.36 (d), 108.26 (d), 54.80 (q), 47.06 (t); HRMS(Q-TOF) for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 307.1441, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 307.1439.</p><p>(<italic>E</italic>)-<italic>N</italic>-(4-chlorobenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-5</bold>) was isolated (0.114&#x02009;g (75.49%)) as yellow powder mp 120&#x02013;125&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.43; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 242 (14854), 325 (Sh, 20225), 346 (23776); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3325, 2924, 1605, 1520, 1473, 953, 818, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.33&#x02013;7.28 (m, 6H, H-Ar), 7.01 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.15&#x02009;Hz, H-Et<sub>1</sub>), 6.99 (s, 1H, H-Ox<sub>4</sub>), 6.70 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.15&#x02009;Hz, H-Et<sub>2</sub>), 6.60 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.39&#x02009;Hz, H-Ar<sub>2</sub>), 4.36 (s, 2H, H-CH<sub>2</sub>), 4.28 (s, 1H, H-NH); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 150.63 (d), 149.23 (s), 147.54 (s), 137.03 (s), 132.58 (s), 129.92 (d), 128.33 (d), 128.12 (d), 127.52 (d), 125.52 (s), 122.11 (d), 112.48 (d), 108.52 (d), 46.88 (t); HRMS(Q-TOF) for C<sub>18</sub>H<sub>15</sub>ClN<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 311.0946, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 311.0938.</p><p>(<italic>E</italic>)-<italic>N</italic>-(4-fluorobenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-6</bold>) was isolated (0.070&#x02009;g (48.95%)) as yellow powder mp 137&#x02013;142&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.43; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 234 (8159), 326 (Sh, 19305), 349 (25076); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3325, 2925, 1606, 1520, 1509, 1470, 953, 818, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.36 (d, 2H, <italic>J</italic><sub>Ar1a,Ar2a</sub> = 8.56&#x02009;Hz, H-Ar<sub>1a</sub>), 7.34 (d, 2H, <italic>J</italic><sub>Ar4b,Ar3b</sub> = 8.83&#x02009;Hz, H-Ar<sub>4b</sub>), 7.05 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.86&#x02009;Hz, H-Et<sub>1</sub>), 7.06 (d, 2H, <italic>J</italic><sub>Ar3b,Ar4b</sub> = 8.83&#x02009;Hz, H-Ar<sub>3</sub>), 6.99 (s, 1H, H-Ox<sub>4</sub>), 6.71 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.32&#x02009;Hz, H-Et<sub>2</sub>), 6.62 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.56&#x02009;Hz, H-Ar<sub>2</sub>), 4.35 (s, 2H, H-CH<sub>2</sub>), 4.24 (s, 1H, H-NH); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz): <italic>&#x003b4;</italic>/ppm 162.44 (s), 150.67 (s), 149.23 (s), 147.66 (s), 134.16 (s), 129.95 (d), 128.48 (d), 128.42 (d), 127.52 (d), 125.43 (d), 122.08 (d), 115.11 (d), 114.97 (d), 112.42 (d), 108.46 (d), 46.88 t); HRMS(Q-TOF) for C<sub>18</sub>H<sub>15</sub>FN<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 295.1241, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 295.1234.</p><p>(<italic>E</italic>)-<italic>N</italic>-(3-methylbenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-7</bold>) was isolated (0.105&#x02009;g (75.18%)) as yellow powder mp 75&#x02013;80&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.31; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 242 (14732), 325 (Sh, 19824), 346 (23783); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3413, 3325, 2921, 1605, 1520, 1489, 1469, 953, 817, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.34&#x02013;7.13 (m, 6H, H-Ar), 7.08 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.54&#x02009;Hz, H-Et<sub>1</sub>), 6.98 (s, 1H, H-Ox<sub>4</sub>), 6.70 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.54&#x02009;Hz, H-Et<sub>2</sub>), 6.63 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.14&#x02009;Hz, H-Ar<sub>2a</sub>), 4.34 (s, 2H, H-CH<sub>2</sub>), 4.23 (s, 1H, H-NH), 2.37 (s, 3H, H-CH<sub>3</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 151.23 (d, C-Ox<sub>2</sub>), 149,73 (s), 148,48 (s), 138, 92 (s), 138,42 (s), 130,57 (d, C-Et<sub>1</sub>), 128,63 (d, C-Ar), 128,23 (d, C-Ar), 128,16 (d, C-Ar), 128,04 (d, C-Ar), 125,65 (s), 124,53 (d, C-Ar), 122,52 (d, C-Ox<sub>4</sub>), 112,86 (d, C-Ar<sub>1a</sub>), 108,75 (d, C-Et<sub>2</sub>), 48,09 (t, C-CH<sub>2</sub>), 21,45 (q, C-CH<sub>3</sub>); HRMS(Q-TOF) for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 291.1492, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 291.1485.</p><p>(<italic>E</italic>)-<italic>N</italic>-(3-methoxybenzyl)-4&#x02013;(2-(oksazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-8</bold>) was isolated (0.080&#x02009;g (53.76%)) as yellow oil: R<sub>f</sub> (DCM, 100%) = 0.27; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 219 (Sh, 13312), 326 (Sh, 11808), 349 (15095); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3307, 2927, 1605, 1522, 1489, 1465, 953, 817, 639; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.33 (d, 2H, <italic>J</italic><sub>Ar1a,Ar2a</sub> = 8.56&#x02009;Hz, H-Ar<sub>1</sub>), 7.02 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub>=16.51&#x02009;Hz, H-Et<sub>1</sub>), 6.98 (s, 1H, H-Ox<sub>4</sub>), 6.97&#x02013;6.90 (m, 1H, H-Ar<sub>5b</sub>), 6.93 (s, 1H, H-Ar<sub>2b</sub>), 6.84 (d, 2H, <italic>J</italic><sub>Ar4b,6b,Ar5b</sub> = 8.00&#x02009;Hz, H-Ar<sub>4b</sub>, H-Ar<sub>6b</sub>), 6.70 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.38&#x02009;Hz, H-Et<sub>2</sub>), 6.63 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.38&#x02009;Hz, H-Ar<sub>2</sub>), 4.36 (s, 2H, H-CH<sub>2</sub>), 4.25 (s, 1H, H-NH), 3.82 (s, 3H, H-OCH<sub>3</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm:133.05 (d), 131.30 (d), 130.05 (d), 129.23 (d), 127.50 (d), 125.47 (d), 125.26 (s), 119.72 (d), 119.13 (d), 112.56 (d), 112.40 (d), 112.19 (d), 108.31 (d), 47.55 (t); HRMS (Q-TOF) for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 307.1441, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 307.1434.</p><p>(<italic>E</italic>)-<italic>N</italic>-(3-chlorobenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-9</bold>) was isolated (0.036&#x02009;g (23.83%)) as yellow oil: Rf (DCM, 100%) = 0.27; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 216 (Sh, 13861), 234 (6874), 329 (Sh, 12349), 347 (14260); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3325, 2925, 1606, 1520, 1473, 953, 818, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.41&#x02013;7.31 (m, 6H, H-Ar), 7.02 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.22&#x02009;Hz, H-Et<sub>1</sub>), 6.99 (s, 1H, H-Ox<sub>4</sub>), 6.71 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.22&#x02009;Hz, H-Et<sub>2</sub>), 6.62 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.48&#x02009;Hz, H-Ar<sub>2a</sub>), 4.38 (s, 2H, H-CH<sub>2</sub>), 4,33 (s, 1H, H-NH); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 158.5 (s), 147.9 (s), 130.4 (s), 130.1 (d), 128.5 (d), 128.4 (s), 128.3 (d), 128.2 (2d), 127.5 (d), 125.2 (s), 122.0 (d), 113.6 (d), 112.5 (d), 112.4 (2d), 108.2 (d), 47.1 (t); HRMS (Q-TOF) for C<sub>18</sub>H<sub>15</sub>ClN<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 311.0946, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 311.0939.</p><p>(<italic>E</italic>)-<italic>N</italic>-(3-fluorobenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-10</bold>) was isolated (0.096&#x02009;g (67.13%)) as yellow powder mp 92&#x02013;95&#x02009;&#x000b0;C;Rf (DCM, 100%) = 0.32; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 226 (30378), 325 (Sh, 14962), 345 (17263); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3419, 2926, 1606, 1520, 1487, 1448, 953, 817, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.32 (d, 2H, <italic>J</italic><sub>Ar1a,Ar2a</sub> = 8.19&#x02009;Hz, H-Ar<sub>1</sub>), 7.18&#x02013;6.99 (m, 4H, H-Ar), 7.02 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.38&#x02009;Hz, H-Et<sub>1</sub>), 6.99 (s, 1H, H-Ox<sub>4</sub>), 6.71 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.38&#x02009;Hz, H-Et<sub>2</sub>), 6.61 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.19&#x02009;Hz, H-Ar<sub>2</sub>), 4.39 (s, 2H, H-CH<sub>2</sub>), 4,32 (s, 1H, H-NH). <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm; 163.5 (s), 161.8 (s), 147.5 (s), 141.3 (s), 129.9 (d), 127.5 (2d), 125.5 (s), 122.2 (d), 122.1 (d), 113.8 (d), 113.7 (d), 113.6 (d), 113.5 (d), 112.4 (2d), 108.5 (d), 47.0 (t); HRMS(Q-TOF) for C<sub>18</sub>H<sub>15</sub>FN<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 295.1241, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 295.1237.</p><p>(<italic>E</italic>)-<italic>N</italic>-(2-methylbenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-11</bold>) was isolated (0.064&#x02009;g (45.35%)) as yellow oil: Rf (DCM, 100%) = 0.30; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 236 (10757), 329 (Sh, 25544), 350 (33604); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3413, 3324, 2923, 1604, 1520, 1495, 1462, 953, 817, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.37&#x02013;7.31 (m, 1H, H-Ar<sub>3</sub>), 7.35 (d, 2H, <italic>J</italic><sub>Ar1a,Ar2a</sub> = 8,81&#x02009;Hz, H-Ar<sub>1a</sub>), 7.26&#x02013;7.18 (m, 1H, H-Ar<sub>4b</sub>), 7.24 (d, 2H, <italic>J</italic><sub>Ar2b,Ar3b</sub> = <italic>J</italic><sub>Ar5b,Ar4b</sub> = 1,70&#x02009;Hz, H-Ar<sub>2</sub>, H-Ar<sub>5</sub>), 7.04 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.48&#x02009;Hz, H-Et<sub>1</sub>), 6.99 (s, 1H, H-Ox<sub>4</sub>), 6.72 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.48&#x02009;Hz, H-Et<sub>2</sub>), 6.64 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.81&#x02009;Hz, H-Ar<sub>2a</sub>), 4.33 (s, 2H, H-CH<sub>2</sub>), 4,10 (s, 1H, H-NH), 2,40 (s, 3H, H-CH<sub>3</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm 150.72 (s), 149.19 (s), 148.03 (s), 136.08 (s), 135.80 (s), 130.09 (d), 130.01 (d), 127.68 (d), 127.54 (d), 127.09 (d), 125.72 (d), 125.17 (d), 122.00 (d), 112.22 (d), 108.28 (d), 45.67 (q), 18.41 (t); HRMS(Q-TOF) for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 291.1492, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 291.1481.</p><p>(<italic>E</italic>)-<italic>N</italic>-(2-methoxybenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline <bold>(</bold><italic>trans</italic><bold>-12</bold>) was isolated (0.050&#x02009;g (33.58%)) as yellow oil: R<sub>f</sub> (DCM, 100%) = 0.18; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 221 (16630), 327 (Sh, 24690), 350 (32084); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3413, 2930, 1605, 1521, 1490, 1463, 953, 817, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.78 (s, 1H, H-Ox<sub>2</sub>), 7.32&#x02013;7.23 (m, 1H, H-Ar<sub>3b</sub>), 7.29 (d, 2H, <italic>J</italic><sub>Ar1aAar2a</sub> = 8.45&#x02009;Hz, H-Ar<sub>1a</sub>), 6.99 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.18&#x02009;Hz, H-Et<sub>1</sub>), 6.96&#x02013;6.88 (m, 3H, H-Ar<sub>2b,3b,4b</sub>), 6.95 (s, 1H, H-Ox<sub>4</sub>), 6.67 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.18&#x02009;Hz, H-Et<sub>2</sub>), 6.63 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.45&#x02009;Hz, H-Ar<sub>2a</sub>), 4.36 (s, 2H, H-CH<sub>2</sub>), 4.33 (s, 1H, H-NH), 3.87 (s, 3H, H-OCH<sub>3</sub>); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm 149.14 (s), 148.24 (s), 130.16 (d), 128.31 (d), 127.98 (d), 127.46 (d), 124.96 (d), 121.90 (d), 120.06 (d), 112.51 (d), 109.84 (d), 108.08 (d), 54.83 (q), 42.75 (t)); HRMS (Q-TOF) for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 307.1441, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 307.1444.</p><p>(<italic>E</italic>)-<italic>N</italic>-(2-fluorobenzyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-14</bold>) was isolated (0.102&#x02009;g (71.52%)) as yellow powder mp 119&#x02013;122&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.26; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 233 (11204), 326 (Sh, 24144), 346 (28843); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3398, 2926, 1605, 1520, 1487, 1455, 952, 815, 758, 638; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.81 (s, 1H, H-Ox<sub>2</sub>), 7.40&#x02013;7.25 (m, 1H, H-Ar<sub>3b</sub>), 7.34 (d, 2H, <italic>J</italic><sub>Ar1a,Ar2a</sub> = 8.15&#x02009;Hz, H-Ar<sub>1a</sub>), 7.14&#x02013;6.97 (m, 3H, H-Ar<sub>2b,3b,4b</sub>), 7.02 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.30&#x02009;Hz, H-Et<sub>1</sub>), 6.99 (s, 1H, H-Ox<sub>4</sub>), 6.70 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.30&#x02009;Hz, H-Et<sub>2</sub>), 6.64 (d, 2H, <italic>J</italic><sub>Ar2a,Ar1a</sub> = 8.15&#x02009;Hz, H-Ar<sub>2a</sub>), 4.45 (s, 2H, H-CH<sub>2</sub>), 4.29 (s, 1H, H-NH); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm 149.37 (s), 147.58 (s), 129.98 (d), 131.84 (d), 128.40 (d), 127.51 (d), 125.46 (d), 123.74 (d), 122.07 (d), 114.88 (d), 112.47 (d), 108.46 (d), 41.17 (t); HRMS(Q-TOF) for C<sub>18</sub>H<sub>15</sub>FN<sub>2</sub>O: (M&#x02009;+&#x02009;H)<sup>+</sup><sub>calcd</sub> = 295.1241, (M&#x02009;+&#x02009;H)<sup>+</sup><sub>found</sub> = 295.1236.</p><p>(<italic>E</italic>)-<italic>N</italic>-(furan-2-ylmethyl)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>trans</italic><bold>-17</bold>) was isolated (0.050&#x02009;g (38.63%)) as yellow powder mp 97&#x02013;102&#x02009;&#x000b0;C; Rf (DCM, 100%) = 0.22; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm (<italic>&#x003b5;</italic>/dm<sup>3</sup>mol<sup>&#x02212;1&#x02009;</sup>cm<sup>&#x02212;1</sup>): 215 (Sh, 16540), 241 (Sh, 10289), 325 (Sh, 22270), 346 (27578); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3407, 2926, 1609, 1519, 1492, 964, 951, 820, 738, 637; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.79 (s, 1H, H-Ox<sub>2</sub>), 7.37 (d, 1H, <italic>J</italic><sub>Fur5,Fur4</sub> = 1.80&#x02009;Hz, H-Fur<sub>5</sub>), 7.32 (d, 2H, <italic>J</italic><sub>Ar1</sub>,<sub>Ar2</sub> = 8.48&#x02009;Hz, H-Ar<sub>1</sub>), 7.00 (d, 1H, <italic>J</italic><sub>Et1,Et2</sub> = 16.60&#x02009;Hz, H-Et<sub>1</sub>), 6.97 (s, 1H, H-Ox<sub>4</sub>), 6.69 (d, 1H, <italic>J</italic><sub>Et2,Et1</sub> = 16.60&#x02009;Hz, H-Et<sub>2</sub>), 6.65 (d, 2H, <italic>J</italic><sub>Ar2,Ar1</sub> = 8.48&#x02009;Hz, H-Ar<sub>2</sub>), 6.32 (dd, 1H, <italic>J</italic><sub>Fur4,Fur5</sub> = 1.81&#x02009;Hz, <italic>J</italic><sub>Fur4,Fur3</sub> = 3.16&#x02009;Hz, H-Fur<sub>4</sub>), 6,24 (d, 1H, <italic>J</italic><sub>Fur3,Fur4</sub> = 3.16&#x02009;Hz, H-Fur<sub>3</sub>), 4.35 (s, 2H, H-CH<sub>2</sub>), 4.21 (s, 1H, H-NH); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm 151.52 (s), 150.64 (s), 149.23 (s), 147.37 (s), 141.55 (d), 129.97 (d), 127.46 (d), 125.66 (d), 122.10 (d), 112.63 (d), 109.87 (d), 108.55 (d), 106.65 (d), 40.69 (t).</p><p>(<italic>E</italic>)-4&#x02013;(2-(oxazol-5-yl)vinyl)-<italic>N</italic>-(thiophen-2-ylmethyl)aniline (<italic>trans</italic><bold>-18</bold>) was isolated (11.1&#x02009;mg (17.10%)) as yellow oil; Rf (DCM) = 0.42; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm: 274 (12817), 291 (13098); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3359, 2811, 1708, 1665; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.62 (s, 1H, H-Ox2), 7.20&#x02013;7.09 (m, 4H), 7.07 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;5.1&#x02009;Hz), 6.98 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;3.2&#x02009;Hz), 6.79 (dd, 1H, <italic>J</italic>&#x02009;=&#x02009;5.1, 3.2&#x02009;Hz), 6.63 (s, 1H), 6.55 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz), 6.23 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz), 4.62 (s, 2H), 4.31 (s, 1H); MS <italic>m/z</italic> (%, fragment) (EI): 282 (M<sup>+</sup>, 100); HRMS (<italic>m/z</italic>): [M&#x02009;+&#x02009;H]<sup>+</sup> calcd for 283.0827; found for 283.0848.</p></sec></sec><sec id="S0004-S2001-S3004" disp-level="3"><label>4.1.4.</label><title>Photochemistry of the new (E)-N-benzyl-4(2-(oxazol-5-yl)vinyl)anilines</title><p>A quartz vessel was charged with (<italic>E</italic>)-<italic>N</italic>-aryl-4(2-(oxazol-5-yl)vinyl)anilines (<italic>trans</italic><bold>-2</bold>&#x02013;<bold>8,</bold>
<italic>trans</italic><bold>-10&#x02013;12</bold> and <italic>trans</italic><bold>-17</bold>) in 50&#x02009;ml of toluene (0.003&#x02009;mmol/mL) with the addition of a small amount of iodine and irradiated at 350&#x02009;nm in the Rayonet reactor for 2&#x02009;h, 3&#x02009;h, 4&#x02009;h and 8&#x02009;h. The conversion was followed by thin-layer chromatography. After irradiation, the solvent was removed in vacuum and the residue chromatographed on a silica gel column using dichloromethane as eluent. In the first fractions, the photoelectrocyclized products <bold>19</bold>&#x02013;<bold>21</bold> were isolated, and in the last fractions the unreacted started amines and photolyzed products <italic>cis</italic>-<bold>18</bold>, <italic>cis</italic>-<bold>22</bold> and <bold>23</bold>.</p><p><italic>N</italic>-benzylnaphtho[1,2-<italic>d</italic>]oxazol-8-amine (<bold>19</bold>) was isolated (25.0&#x02009;mg (37.40%)) as yellow oil; R<sub>f</sub> (DCM) = 0.53; UV (EtOH) <italic>&#x003bb;<sub>max</sub></italic>/nm: 247 (15132), 299 (5098), 344 (4899); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3396, 2922, 2849, 1735, 1635, 1535; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 8.15 (s, 1H, H-Ox2), 7.75 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz), 7.66 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz), 7.52 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz), 7.43 (t, 3H, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz), 7.35 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz), 7.31&#x02013;7.28 (m, 1H), 6.94 (dd, 1H, <italic>J</italic>&#x02009;=&#x02009;8.7; 2.5&#x02009;Hz), 4.52 (s, 2H); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 149.7 (s), 146.2 (s), 138.2 (s), 129.3 (2d), 128.2 (d), 128.7 (s), 127.7 (s), 127.3 (2d), 126.9 (d), 126.4 (d), 125.9 (d), 124.2 (s), 116.1 (d); 105.9 (d), 98.8 (d), 47.8 (t); MS <italic>m/z</italic> (%, fragment) (EI): 274 (M<sup>+</sup>, 100); HRMS (<italic>m/z</italic>): [M&#x02009;+&#x02009;H]<sup>+</sup> calcd for 275.1106; found for 275.1119.</p><p><italic>N</italic>-(4-fluorobenzyl)naphtho[1,2-<italic>d</italic>]oxazol-8-amine (<bold>20</bold>) was isolated (18.6&#x02009;mg (26.4%)) as yellow oil; R<sub>f</sub> (DCM) = 0.55; UV (EtOH) <italic>&#x003bb;<sub>max</sub></italic>/nm: 247 (5711), 310 (4677), 339 (2013); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3414, 2922, 1637, 1601, 1533, 1508, 1255, 1222; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 8.11 (s, 1H, H-Ox2), 7.75 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz), 7.66 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz), 7.49 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;2.5&#x02009;Hz), 7.43 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8.3&#x02009;Hz), 7.42&#x02013;7.39 (m, 2H), 7.04 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz), 6.94 (dd, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8; 2.5&#x02009;Hz), 4.50 (s, 2H), 4.39 (s, 1H, NH); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 163.7 (s), 150.8 (s), 148.2 (s), 146.9 (s), 134.5 (s), 129.8 (d), 129.3 (d), 129.2 (d), 126.4 (d), 124.7 (s), 116.5 (d), 115.7 (d), 115.4 (d), 106.6 (d), 99.3 (d); 47.5 (t); MS <italic>m/z</italic> (%, fragment) (EI): 292 (M<sup>+</sup>, 100); HRMS (<italic>m/z</italic>): [M&#x02009;+&#x02009;H]<sup>+</sup> calcd for 293.1012; found for 293.1004.</p><p><italic>N</italic>-(thiophen-2-ylmethyl)naphtho[1,2-<italic>d</italic>]oxazol-8-amine (<bold>21</bold>) was isolated (8.5&#x02009;mg (13.0%)) as yellow oil; R<sub>f</sub> (DCM) = 0.67; UV (EtOH) <italic>&#x003bb;<sub>max</sub></italic>/nm: 231 (19138); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3393, 2917, 2310, 1731, 1539, 1460; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 8.16 (s, 1H, H-Ox2), 7.76 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz), 7.67 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz), 7.56 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;2.3&#x02009;Hz), 7.44 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz), 7.24 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;5.0&#x02009;Hz), 7.10 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;3.5&#x02009;Hz), 6.99 (dd, 1H, <italic>J</italic>&#x02009;=&#x02009;5.0, 3.5&#x02009;Hz), 6.95 (dd, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8; 2.5&#x02009;Hz), 4.71 (s, 2H), 4.40 (s, 1H); <sup>13&#x02009;</sup>C NMR (CDCl<sub>3</sub>, 75&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 153.7 (s), 149.3 (s), 136.9 (s), 129.9 (d), 128.7 (d), 128.1 (d), 127.5 (s), 127.0 (d), 126.6 (d), 125.3 (d), 124.4 (s), 116.4 (d), 106.2 (d), 99.5 (d), 50.1 (t); MS <italic>m/z</italic> (%, fragment) (EI): 280 (M<sup>+</sup>, 100); HRMS (<italic>m/z</italic>): [M&#x02009;+&#x02009;H]<sup>+</sup> calcd for 281.0670; found for 281.0691.</p><p>(<italic>Z</italic>)-4&#x02013;(2-(oxazol-5-yl)vinyl)-<italic>N</italic>-(thiophen-2-ylmethyl)aniline (<italic>cis</italic>-<bold>18</bold>) was isolated (11.1&#x02009;mg (17.10%)) as yellow oil; R<sub>f</sub> (DCM) = 0.42; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm: 274 (12817), 291 (13098); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3359, 2811, 1708, 1665; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.62 (s, 1H, H-Ox2), 7.20&#x02013;7.09 (m, 4H), 7.07 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;5.1&#x02009;Hz), 6.98 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;3.2&#x02009;Hz), 6.79 (dd, 1H, <italic>J</italic>&#x02009;=&#x02009;5.1, 3.2&#x02009;Hz), 6.63 (s, 1H), 6.55 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz), 6.23 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz), 4.62 (s, 2H), 4.31 (s, 1H); MS m/z (%, fragment) (EI): 282 (M+, 100); HRMS (m/z): [M&#x02009;+&#x02009;H]+ calcd for 283.0827; found for 283.0848.</p><p>(<italic>Z</italic>)-4&#x02013;(2-(oxazol-5-yl)vinyl)aniline (<italic>cis-</italic><bold>22</bold>) was isolated (4.5&#x02009;mg (7.2%)) as yellow oil; R<sub>f</sub> (DCM) = 0.43; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm: 259 (13474), 265 (12817), 272 (13409); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3412, 2917, 2844, 1737, 1632, 1462; UV (EtOH) <italic>&#x003bb;</italic><sub>max</sub>/nm: 259 (13474), 265 (12817), 272 (13409); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.73 (s, 1H, H-Ox2), 7.40&#x02013;7.33 (m, 4H), 7.32 (s, 2H), 6.91 (s, 1H), 6.67 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;12.5&#x02009;Hz), 6.39 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;12.5&#x02009;Hz); MS <italic>m/z</italic> (%, fragment) (EI): 186 (M<sup>+</sup>, 100); HRMS (<italic>m/z</italic>): [M&#x02009;+&#x02009;H]<sup>+</sup> calcd for 186.0793; found for 186.0782.</p><p>Naphtho[1,2-<italic>d</italic>]oxazol-8-amine (<bold>23</bold>) was isolated (3.9&#x02009;mg (6.4%)) as yellow oil; R<sub>f</sub> (PE/DCM = 1:1) = 0.23; UV (EtOH) <italic>&#x003bb;<sub>max</sub></italic>/nm: 225 (18143), 353 (4881), 400 (4012); IR <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup> (NaCl): 3414, 2922, 1637, 1601, 1533, 1508, 1255, 1222; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>/ppm: 7.37 (s, 1H, H-Ox2), 7.34 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz), 6.93 (s, 1H), 6.86 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;10.0&#x02009;Hz), 6.72 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz), 6.65 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;10.0&#x02009;Hz), 3.01 (s, 2H, NH<sub>2</sub>); MS <italic>m/z</italic> (%, fragment) (EI): 184 (M<sup>+</sup>, 100); HRMS (<italic>m/z</italic>): [M&#x02009;+&#x02009;H]<sup>+</sup> calcd for 185.0637; found for 185.0644.</p></sec></sec><sec id="S0004-S2002" disp-level="2"><label>4.2.</label><title>Reversible inhibition of cholinesterases by novel oxazole benzylamine compounds</title><p>Inhibition potency of novel compounds was evaluated for recombinant human AChE (prepared as described earlier<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref> and kindly donated by Prof Palmer Taylor, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, USA) and BChE isolated from human plasma (kindly donated by late Dr Douglas Cerasoli and Dr David Lenz, USAMRICD, Edgewood, MD). The inhibition mixture contained a 0.1&#x02009;M phosphate buffer, pH 7.4, enzyme, tested compound, and reagent, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, 0.3&#x02009;mM; Sigma Chemical Co., St. Louis, MO, USA). Enzyme activity was measured upon addition of substrate, acetylthiocholine (ATCh, 0.2 or 0.1&#x02009;mM; Sigma Chemical Co., St. Louis, MO, USA) by the Ellman method<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref> at 25&#x02009;&#x000b0;C and 412&#x02009;nm, on a Tecan Infinite M200PRO plate reader (Tecan Austria, GmbH, Salzburg, Austria). Due to the low solubility, a stock solution of the tested compounds was prepared in DMSO or methanol (Kemika, Zagreb, Croatia), and a corresponding solvent was in controls as well. The IC<sub>50</sub> values were determined from at least three experiments by a nonlinear fit of the compound concentration logarithm values vs. % of enzyme activity using Prism6 software (GraphPad Prism 6 Software, San Diego, USA).</p></sec></sec><sec sec-type="supplementary-material" id="S0005" disp-level="1"><title>Supporting information</title><p><sup>1</sup>H and <sup>13&#x02009;</sup>C NMR spectra of all the newly synthesised and isolated compounds, along with the 2&#x02009;D NMR spectra of some compounds as well as AChE inhibition by <italic>trans-</italic>amino-5-arylethenyl-oxazole derivatives.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM5345"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1707197_SM5345.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgement</title><p>The University of Zagreb short term scientific support under the title <italic>Synthesis and functionalization of novel (hetero)polycyclic photoproducts as potential cholinesterase inhibitors</italic> is gratefully acknowledged. The competent help by &#x0017d;eljko Marini&#x00107; in the NMR measurements is also appreciated.</p></ack><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Radi&#x00107;</surname>
<given-names>Z.</given-names></string-name></person-group>
<article-title>The cholinesterases: from genes to proteins</article-title>. <source>Annu Rev Pharmacol Toxicol</source>
<year>1994</year>;<volume>33</volume>:<fpage>281</fpage>&#x02013;<lpage>320</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sussman</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Harel</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Frolow</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Atomic structure of acetylcholinesterase from Torpedo Californica: a prototypic acetylcholine-binding protein</article-title>. <source>Science</source>
<year>1991</year>;<volume>253</volume>:<fpage>872</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">1678899</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kovarik</surname>
<given-names>Z.</given-names></string-name></person-group>
<article-title>Amino acid residues conferring specificity of cholinesterases</article-title>. <source>Period Biol</source>
<year>1999</year>;<volume>101</volume>:<fpage>7</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Radi&#x00107;</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Pickering</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Vellom</surname>
<given-names>DC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors</article-title>. <source>Biochemistry</source>
<year>1993</year>;<volume>32</volume>:<fpage>12074</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">8218285</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saxena</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Redman</surname>
<given-names>AMG</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>X</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Differences in active-site gorge dimensions of cholinesterase revealed by binding of inhibitors to human butyrylcholinesterase</article-title>. <source>Chem Biol Interact</source>
<year>1999</year>;<volume>119&#x02009;&#x02013;&#x02009;120</volume>:<fpage>61</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Radi&#x00107;</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Hosea</surname>
<given-names>NA</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural bases for the specificity of cholinesterase catalysis and inhibition</article-title>. <source>Toxicol Lett</source>
<year>1995</year>;<volume>82&#x02009;&#x02013;&#x02009;83</volume>:<fpage>453</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Soreq</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Seidman</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Acetylcholinesterase &#x02013; new roles for an old actor</article-title>. <source>Nat Rev Neurosci</source>
<year>2001</year>;<volume>2</volume>:<fpage>294</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">11283752</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silman</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Sussman</surname>
<given-names>JL.</given-names></string-name></person-group>
<article-title>Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology</article-title>. <source>Curr Opin Pharmacol</source>
<year>2005</year>;<volume>5</volume>:<fpage>293</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">15907917</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pienica</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Soreq</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>MicroRNA regulators of cholinergic signaling link neuromuscular, cardiac and metabolic systems</article-title>. <source>Period Biol</source>
<year>2016</year>;<volume>118</volume>:<fpage>373</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chatonnet</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lockridge</surname>
<given-names>O.</given-names></string-name></person-group>
<article-title>Comparison of butyrylcholinesterase and acetylcholinesterase</article-title>. <source>Biochem J</source>
<year>1989</year>;<volume>260</volume>:<fpage>625</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">2669736</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>&#x000c7;okugras</surname>
<given-names>AN.</given-names></string-name></person-group>
<article-title>Butyrylcholinesterase: structure and physiological importance</article-title>. <source>Turk J Biochem</source>
<year>2003</year>;<volume>28</volume>:<fpage>54</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mesulam</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Guillozet</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shaw</surname>
<given-names>P</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine</article-title>. <source>Neuroscience</source>
<year>2002</year>;<volume>110</volume>:<fpage>627</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">11934471</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guillozet</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Mesulam</surname>
<given-names>M-M</given-names></string-name>, <string-name><surname>Smiley</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Mash</surname>
<given-names>DC.</given-names></string-name></person-group>
<article-title>Butyrylcholinesterase in the life cycle of amyloid plaques</article-title>. <source>Ann Neurol</source>
<year>1997</year>;<volume>42</volume>:<fpage>909</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">9403484</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mesulam</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Geula</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia</article-title>. <source>Ann Neurol</source>
<year>1994</year>;<volume>36</volume>:<fpage>722</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7979218</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Darvesh</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Walsh</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>R</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of human cholinesterases by drugs used to treat alzheimer disease</article-title>. <source>Alzheimer Dis Assoc Disord</source>
<year>2003</year>;<volume>17</volume>:<fpage>117</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">12794390</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bosak</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rami&#x00107;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>&#x00160;midlehner</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold</article-title>. <source>PLoS One</source>
<year>2018</year>;<volume>13</volume>:<fpage>e0205193</fpage>.<pub-id pub-id-type="pmid">30289893</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bosak</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Opsenica</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>&#x00160;inko</surname>
<given-names>G</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase</article-title>. <source>Chem Biol Interact</source>
<year>2019</year>;<volume>308</volume>:<fpage>101</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31100281</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katalini&#x00107;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bosak</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kovarik</surname>
<given-names>Z.</given-names></string-name></person-group>
<article-title>Flavonoids as inhibitors of human butyrylcholinesterase variants</article-title>. <source>Food Technol Biotechnol</source>
<year>2014</year>;<volume>52</volume>:<fpage>64</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>&#x00160;agud</surname>
<given-names>I</given-names></string-name>, <string-name><surname>&#x00160;kori&#x00107;</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Bur&#x0010d;ul</surname>
<given-names>F.</given-names></string-name></person-group>
<article-title>Naphthoxazoles and heterobenzoxazoles: cholinesterase inhibiting and antioxidant activity</article-title>. <source>Turk J Chem</source>
<year>2019</year>;<volume>43</volume>:<fpage>118</fpage>&#x02013;<lpage>24</lpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>&#x00160;agud</surname>
<given-names>I</given-names></string-name>, <string-name><surname>&#x00160;indler-Kulyk</surname>
<given-names>M</given-names></string-name>, <string-name><surname>&#x00160;kori&#x00107;</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of naphthoxazoles by photocyclization of 4-/5-(phenylethenyl)oxazoles</article-title>. <source>Eur J Org Chem</source>
<year>2018</year>;<volume>2018</volume>:<fpage>3326</fpage>&#x02013;<lpage>35</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fors</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Krattiger</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Strieter</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Buchwald</surname>
<given-names>SL.</given-names></string-name></person-group>
<article-title>Water-mediated catalyst preactivation: an efficient protocol for C-N cross-coupling reactions</article-title>. <source>Org Lett</source>
<year>2008</year>;<volume>10</volume>:<fpage>3505</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18620415</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Giacobini</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Cholinesterase inhibitors: new roles and therapeutic alternatives</article-title>. <source>Pharmacol Res</source>
<year>2004</year>;<volume>50</volume>:<fpage>433</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">15304240</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Darreh-Shori</surname>
<given-names>T.</given-names></string-name></person-group>
<article-title>DMSO: a mixed-competitive inhibitor of human acetylcholinesterase</article-title>. <source>ACS Chem Neurosci</source>
<year>2017</year>;<volume>8</volume>:<fpage>2618</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">29017007</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Leusen</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Hoogenboom</surname>
<given-names>BE</given-names></string-name>, <string-name><surname>Siderius</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>A novel and efficient synthesis of oxazoles from tosylmethylisocyanide and carbonyl compounds</article-title>. <source>Tetrahedron Letters</source>
<year>1972</year>;<volume>13</volume>:<fpage>2369</fpage>&#x02013;<lpage>72</lpage>.</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cochran</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kalisiak</surname>
<given-names>J</given-names></string-name>, <string-name><surname>K&#x000fc;&#x000e7;&#x000fc;kkilin&#x000e7;</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Oxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging</article-title>. <source>J Biol Chem</source>
<year>2011</year>;<volume>286</volume>:<fpage>29718</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">21730071</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ellman</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>Courtney</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Andres</surname>
<given-names>V</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Featherstone</surname>
<given-names>RM.</given-names></string-name></person-group>
<article-title>New and rapid colorimetric determination of acetylcholinesterase activity</article-title>. <source>Biochem Pharmacol</source>
<year>1961</year>;<volume>7</volume>:<fpage>88</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">13726518</pub-id></mixed-citation></ref></ref-list></back></article>